Truffle Capital, a private equity firm, led a $24m funding round in Cellaïon, a biotechnology company active in the field of cell therapy, with participation from Medeor, Newton Biocapital and WE. “I am pleased with the enthusiasm generated by the technology and Cellaïon's mission to save the lives of patients with severe liver failure. HepaStem® is an innovative treatment based on hepatic stem cells; HepaStem® acts on several parameters responsible for hyperinflammation, in order to restore liver function. The ongoing study aims to demonstrate its efficacy and good tolerance with a view to bringing this product to the market, for the benefit of patients,” Etienne Sokal, Cellaïon CEO and Founder.